Amedisys, Inc.
AMED
NASDAQ
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 571.41M | 570.79M | 556.24M | 552.97M | 556.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 571.41M | 570.79M | 556.24M | 552.97M | 556.39M |
| Cost of Revenue | 321.54M | 321.42M | 311.63M | 297.46M | 315.01M |
| Gross Profit | 249.88M | 249.37M | 244.61M | 255.51M | 241.38M |
| SG&A Expenses | 193.32M | 199.70M | 192.98M | 212.99M | 193.84M |
| Depreciation & Amortization | 4.27M | 4.14M | 4.44M | 4.73M | 4.44M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 519.13M | 525.26M | 509.05M | 515.17M | 513.29M |
| Operating Income | 52.29M | 45.53M | 47.19M | 37.80M | 43.10M |
| Income Before Tax | 27.23M | 29.20M | 37.95M | -62.23M | 34.71M |
| Income Tax Expenses | 12.63M | 10.18M | 12.33M | 18.25M | 9.80M |
| Earnings from Continuing Operations | 14.59M | 19.02M | 25.62M | -80.48M | 24.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -194.00K | 302.00K | 344.00K | 206.00K | 337.00K |
| Net Income | 14.40M | 19.32M | 25.96M | -80.28M | 25.25M |
| EBIT | 52.29M | 45.53M | 47.19M | 37.80M | 43.10M |
| EBITDA | 58.42M | 51.42M | 53.25M | 43.99M | 48.79M |
| EPS Basic | 0.44 | 0.59 | 0.80 | -2.46 | 0.78 |
| Normalized Basic EPS | 0.91 | 0.79 | 0.83 | 0.85 | 0.69 |
| EPS Diluted | 0.44 | 0.58 | 0.79 | -2.46 | 0.77 |
| Normalized Diluted EPS | 0.90 | 0.78 | 0.83 | 0.85 | 0.69 |
| Average Basic Shares Outstanding | 32.67M | 32.64M | 32.62M | 32.58M | 32.56M |
| Average Diluted Shares Outstanding | 32.98M | 32.91M | 32.83M | 32.58M | 32.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
